



This list of clinical research protocols relating to prostate cancer is compiled for your convenience.

For more information on these protocols, please call PDQ, a service of the National Cancer Institute, at 1-800-4-CANCER. The PDQ Web site is accessible at <http://cancer.net.nci.nih.gov/trialsrch.shtml>.

A searchable Web site developed by the National Library of Medicine is also available at <http://clinicaltrials.gov>.

SELECTED CLINICAL RESEARCH PROTOCOLS FOR PROSTATE CANCER

NCI High Priority

VA-CSP-407, NCI-T94-01310, PIVOT-1 Phase III Randomized Study of Prostatectomy Versus Expectant Management With Palliative Therapy in Patients With Clinically Localized Prostate Cancer (PIVOT)

Chairperson: Timothy James Wilt. Telephone: 612-725-2158. Lead organization: Veterans Affairs Cooperative Studies Program Coordinating Center - Perry Point. Age range: 75 and under.

Stage I and II

E-3899 Phase II Randomized Study of Mitoxantrone, Estramustine, and Vinorelbine Versus Isotretinoin, Interferon alfa, and Paclitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer

Chairperson: Robert S. DiPaola. Telephone: 732-235-7469. Lead organization: Eastern Cooperative Oncology Group. Age range: 18 and over.

SWOG-S9921, CTSU Phase III Randomized Study of Adjuvant Androgen Deprivation Therapy With or Without Mitoxantrone and Prednisone Following Radical Prostatectomy in Patients With High-Risk Localized Prostate Cancer

Chairperson: L. Michael Glode. Telephone: 720-848-0170. Lead organization: Southwest Oncology Group. Age range: 30 to 85.

RTOG-9902, RTOG-DEV-1020 Phase III Randomized Study of Androgen Suppression and Radio-

therapy With or Without Subsequent Paclitaxel, Estramustine, and Etoposide in Patients With Localized, High Risk Prostate Cancer

Chairperson: Howard Mark Sandler. Telephone: 734-936-9338. Lead organization: Radiation Therapy Oncology Group. Age range: over 18.

ACOSOG-Z0070 Phase III Randomized Study of Radical Prostatectomy Versus Brachytherapy in Patients With Stage I or II Prostate Cancer

Chairperson: Samuel A. Wells, Jr. Telephone: 312-202-5208. Lead organization: American College of Surgeons Oncology Group. Age range: 75 and under.

Stage IV

CLB-90006 Phase II Study of Bevacizumab, Estramustine, and Docetaxel in Patients With Hormone-Refractory Metastatic Prostate Cancer

Chairperson: Joel Picus. Telephone: 314-747-1367. Lead organization: Cancer and Leukemia Group B. Age range: any age.

SWOG-S0111, CTSU Phase II Study of BMS-247550 in Patients With Hormone-Refractory Prostate Cancer

Chairperson: Maha Hadi A. Hussain. Telephone: 313-745-2357. Lead organization: Southwest Oncology Group. Age range: not specified.

SWOG-S9916 Phase III Randomized Study of Docetaxel and Estramustine vs Mitoxantrone and

Prednisone in Patients With Advanced Hormone Refractory Prostate Cancer

Chairperson: Daniel P. Petrylak. Telephone: 212-305-1731. Lead organization: Southwest Oncology Group. Age range: 18 and over.

SWOG-9346, CAN-NCIC-JPR8, INT-0162 Phase III Randomized Study of Intermittent Versus Constant Combined Androgen Deprivation (Bicalutamide and Goserelin) in Patients With Stage IV Prostate Cancer Responsive to Such Therapy

Chairperson: Maha Hadi A. Hussain. Telephone: 313-745-2357. Lead organization: Southwest Oncology Group. Age range: adult.

Radiation

RTOG-P-0019, RTOG-DEV-1064 Phase II Study of External Beam Radiotherapy Followed By Permanent Source Brachytherapy Using Interstitial Iodine I 125 Seeds in Patients With Intermediate Risk, Clinically Localized Adenocarcinoma of the Prostate

Chairperson: William Robert Lee. Telephone: 336-716-4464. Lead organization: Radiation Therapy Oncology Group. Age range: over 18.

RTOG-P-0011, CTSU, RTOG-DEV-1037 Phase III Randomized Adjuvant Study of Radiotherapy With Hormonal Therapy Versus Radiotherapy Alone Versus Hormonal Therapy Alone in Patients With High-Risk Stage III Prostate Cancer

Chairperson: Walter John Cur-

ran, Jr. Telephone: 215-955-6700. Lead organization: Radiation Therapy Oncology Group. Age range: not specified.

RTOG-9910, CTSU Phase III Randomized Study of Neoadjuvant Total Androgen Suppression and Radiotherapy in Patients With Intermediate-Risk Adenocarcinoma of the Prostate

Chairperson: Thomas Michael Pisansky. Telephone: 507-284-4655. Lead organization: Radiation Therapy Oncology Group. Age range: 18 and over.

RTOG-9714, NCI-P97-0124 Phase III Randomized Study of Palliative Radiation Therapy for Bone Metastases From Breast or Prostate Cancer

Chairperson: William F. Hartsell. Telephone: 847-723-8030. Lead organization: Radiation Therapy Oncology Group. Age range: 18 and over.

EORTC-22991 Phase III Randomized Study of Radiotherapy With or Without Adjuvant Bicalutamide and Goserelin in Patients With Localized Prostate Cancer

Chairperson: Michel Bolla. Telephone: +33-4-76-765506. Lead organization: EORTC Radiotherapy Group. Age range: 80 and under.

FRE-FNCLCC-GETUG-01, EU-98029 Phase III Randomized Study of Radiotherapy to the Prostate With or Without Radiotherapy to the Pelvis in Patients With Stage I, II, or III Adenocarcinoma of the Prostate

Chairperson: Pascal Pommier. Telephone: +33-4-78-782648. Lead

organization: Federation Nationale des Centres de Lutte Contre le Cancer. Age range: 75 and under.

RTOG-9601, RTOG-R9601, CTSU Phase III Randomized Study of Radiotherapy With or Without Bicalutamide in Patients With PSA Elevation Following Radical Prostatectomy for Carcinoma of the Prostate

Chairperson: William U. Shipley. Telephone: 617-726-8146. Lead organization: Radiation Therapy Oncology Group. Age range: any age.

RTOG-9408 Phase III Randomized Study of Radiotherapy With or Without Neoadjuvant Flutamide Plus Goserelin or Leuprolide in Patients With Good Prognosis, Locally Confined Adenocarcinoma of the Prostate

Chairperson: David G. McGowan. Telephone: 780-432-8755. Lead organization: Radiation Therapy Oncology Group. Age range: any age.

CAN-NCIC-PR3, NCI-T94-01100, EU-99013 Phase III Randomized Study of Total Androgen Blockade With or Without Pelvic Irradiation in Patients With Locally Advanced Adenocarcinoma of the Prostate

Chairperson: Pdraig R. Warde. Telephone: 416-946-2122. Lead organization: NCIC-Clinical Trials Group. Age range: under 80.

FRE-FNCLCC-PAC-GETUG-06-99001, EU-20037 Phase III Randomized Study of Two Different Radiotherapy Regimens Using Different Doses and Number of Frac-

tions in Patients With Localized Prostate Cancer

Chairperson: P. Bey, Chair. Telephone: +33-03-83-59-8400. Lead organization: Federation Nationale des Centres de Lutte Contre le Cancer. Age range: Under 75.

Dietary Change

MSKCC-98014, NCI-G98-1445 Phase III Randomized Study of the Effect of a Diet Low in Fat and High in Soy, Fruits, Vegetables, Green Tea, Vitamin E, and Fiber on PSA Levels in Patients With Prostate Cancer

Chairperson: Moshe Shike. Telephone: 212-639-7846. Lead organization: Memorial Sloan-Kettering Cancer Center. Age range: 18 and over.

UCLA-0001030, NCI-G01-1973 Phase II Randomized Study of the Effects of a Low Fat, High Fiber Diet or Androgen Deprivation Therapy on Serum Factors in Patients With Prostate Cancer

Chairperson: William Aaronson. Telephone: 310-268-3446. Lead organization: Jonsson Comprehensive Cancer Center, University of California, Los Angeles. Age range: 40 to 80.

SWOG-0000, NCI-P00-0172 Phase III Randomized Study of Selenium and Vitamin E for the Prevention of Prostate Cancer (SELECT Trial)

Chairperson: Eric Klein. Telephone: 216-444-5591. Lead organization: Southwest Oncology Group. Age range: 55 and over (50 and over for African Americans).